AbbVie Q3 sales up 3%; Humira sales down 4%

AbbVie (ABBV) Q3 results: Revenues: $8,479M (+3.0%); Immunology: $5,041M (-1.6%); Hematologic Oncology: $1,478M (+38.3%); HCV: $698M (-19%).

Net Income: $1,884M (-31.4%); EPS: $1.26 (-30.4%); non-GAAP Net Income: $3,468M (+6.5%); non-GAAP EPS: $2.33 (+8.9%).

Key product sales: Humira: $4,936M (-3.7%); Imbruvica: $1,257M (+29.3%); Mavyret: $695M (-17.1%); Venclexta: $221M; Skyrizi: $91M.

2019 guidance: EPS: $5.08 – 5.10 from $5.69 – 5.79; non-GAAP EPS: $8.90 – 8.92 from $8.82 – 8.92.

https://seekingalpha.com/news/3512984-abbvie-q3-sales-3-percent-humira-sales-4-percent